Scientific paper - Review paper
The utility of cfDNA in TGCT patient management: a systematic review
Therapeutic Advances in Medical Oncology, 14 (2022); 17588359221090365. https://doi.org/10.1177/17588359221090365


Cite this document

Krasić, J., Škara, L., Katušić Bojanac, A., Ulamec, M., Ježek, D., Kuliš, T. & Sinčić, N. (2022). The utility of cfDNA in TGCT patient management: a systematic review. Therapeutic Advances in Medical Oncology, 14.. doi: 10.1177/17588359221090365

Krasić, Jure, et al. "The utility of cfDNA in TGCT patient management: a systematic review." Therapeutic Advances in Medical Oncology, vol. 14, 2022. https://doi.org/10.1177/17588359221090365

Krasić, Jure, Lucija Škara, Ana Katušić Bojanac, Monika Ulamec, Davor Ježek, Tomislav Kuliš and Nino Sinčić. "The utility of cfDNA in TGCT patient management: a systematic review." Therapeutic Advances in Medical Oncology 14 (2022). https://doi.org/10.1177/17588359221090365

Krasić, J., et al. (2022) 'The utility of cfDNA in TGCT patient management: a systematic review', Therapeutic Advances in Medical Oncology, 14. doi: 10.1177/17588359221090365

Krasić J, Škara L, Katušić Bojanac A, Ulamec M, Ježek D, Kuliš T, and sur.. The utility of cfDNA in TGCT patient management: a systematic review. Therapeutic Advances in Medical Oncology [Internet]. 2022 May 31 [cited 2024 June 18];14. doi: 10.1177/17588359221090365

J. Krasić, et al., "The utility of cfDNA in TGCT patient management: a systematic review", Therapeutic Advances in Medical Oncology, vol. 14, May 2022. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:105:343249. [Accessed: 18 June 2024]